Thomas Catinazzo - 30 Mar 2021 Form 4/A - Amendment Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
Senior Vice President, Finance
Signature
/s/ Brian Adams, as Attorney-in-Fact
Issuer symbol
RLAY
Transactions as of
30 Mar 2021
Net transactions value
-$694,800
Form type
4/A - Amendment
Filing time
09 Jun 2021, 20:33:17 UTC
Date Of Original Report
01 Apr 2021
Next filing
09 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Options Exercise $92,700 +22,500 +142% $4.12 38,370 30 Mar 2021 Direct F1
transaction RLAY Common Stock Sale $787,500 -22,500 -59% $35.00 15,870 30 Mar 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLAY Stock Option (Right to Buy) Options Exercise $0 -22,500 -17% $0.000000 107,043 30 Mar 2021 Common Stock 22,500 $4.12 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2020.
F2 Twenty-five percent (25%) of the shares underlying this option vested on April 9, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

Remarks:

The Form 4 filed on April 1, 2020 by the reporting person inadvertently understated the number of shares beneficially owned following the reported transactions by 15,870 shares in Column 5 of Table I.